Arvinas, Inc., a pioneering biotechnology company headquartered in the United States, is at the forefront of developing innovative therapies through its proprietary PROTAC® (Proteolysis Targeting Chimera) technology. Founded in 2013, Arvinas has made significant strides in the biopharmaceutical industry, focusing on targeted protein degradation to address unmet medical needs in oncology and other serious diseases. With a strong operational presence in key regions across the US, Arvinas is dedicated to advancing its pipeline of drug candidates, which uniquely harness the body's natural degradation mechanisms to eliminate disease-causing proteins. The company has garnered attention for its strategic partnerships and collaborations, positioning itself as a leader in the field of targeted therapies. Arvinas continues to push the boundaries of science, aiming to transform the treatment landscape for patients worldwide.
How does Arvinas, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Arvinas, Inc.'s score of 25 is lower than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Arvinas, Inc., headquartered in the US, currently does not have available carbon emissions data for the most recent year, nor does it report specific reduction targets or initiatives. The company has not disclosed any commitments to the Science Based Targets initiative (SBTi) or other climate pledges. As such, there are no specific figures regarding their carbon footprint, including Scope 1, 2, or 3 emissions. Without concrete emissions data or reduction targets, it is unclear how Arvinas, Inc. is addressing climate change within its operations. The absence of reported initiatives suggests a potential area for development in their sustainability strategy.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Arvinas, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
